NETHERLANDS - Institutional investors could increase their weightings in pharmaceutical firms if the industry examines a new study, according to Martin Eijgenhuijsen senior portfolio manager at ABP Investments.
Eijgenhuijsen reportedly made the comments after the conclusions of the Pharma Futures report were published yesterday.
The study urged the industry to shift to more targeted portfolios and to strategically restructure research and development in order to provide future value for shareholders and society.
Eijgenhuijsen reportedly said: “It will be interesting to see whether catalysts might occur to make it attractive to increase our weightings in the pharmaceuticals sector.”
He added: “We would like to see increased R&D transparency and a bigger percentage of biological and innovative, novel drugs and a declining percentage of incremental variation.”
Eijgenhuijsen was also said to have urged the pharmaceutical industry to focus on specific disease areas and integrate different business models as this could potentially create a complementary source of alpha.
His comments came after ABP, together with other institutions, has spent a year engaging with pharmaceutical firms to discuss challenges facing the industry.
As a result, the senior investment officer predicted that pension funds may examine the energy sector next.
He reportedly said: “The model initiated by the Pharma Futures study can be applied to other sectors, particularly those which attract negative publicity such as energy.”
Partner Insight: Members' evolving needs and expectations are driving changes in scheme administration. As the pensions landscape inevitably continues to change, how will your scheme's approach need to develop to keep pace?
The Pensions Regulator (TPR) is "working closely" with government contractor Interserve and the trustees of its defined benefit (DB) pension schemes, it has confirmed.
The industry has welcomed the Department for Work and Pensions' (DWP) consultation on defined benefit (DB) consolidation as a way to address scheme covenant issues.
BMO Global Asset Management has opened a UK fiduciary management business, promising a "truly open architecture" approach to deliver "better client outcomes".